-
Product Insights
NewNet Present Value Model: Daiichi Sankyo Co Ltd’s Patritumab deruxtecan
Empower your strategies with our Net Present Value Model: Daiichi Sankyo Co Ltd's Patritumab deruxtecan report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Kalvista Pharmaceuticals Inc’s Sebetralstat
Empower your strategies with our Net Present Value Model: Kalvista Pharmaceuticals Inc's Sebetralstat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Takeda Pharmaceutical Co Ltd’s Soticlestat
Empower your strategies with our Net Present Value Model: Takeda Pharmaceutical Co Ltd's Soticlestat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fortress Biotech Inc’s CUTX-101
Empower your strategies with our Net Present Value Model: Fortress Biotech Inc's CUTX-101 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Theralase Technologies Inc’s TLD-1433
Empower your strategies with our Net Present Value Model: Theralase Technologies Inc's TLD-1433 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pomalidomide in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pomalidomide in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pomalidomide in Myelodysplastic Syndrome Drug Details: Pomalidomide (Pomalyst / Imnovid) is...
-
Thematic Analysis
NewConstruction M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Construction Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986454 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986454 in Autoimmune Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986454 in Autoimmune Disorders Drug Details: BMS-986454 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Helios CELMoD in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Helios CELMoD in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Helios CELMoD in Solid Tumor Drug Details: The therapeutic candidate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986465 in Neuroinflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986465 in Neuroinflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986465 in Neuroinflammation Drug Details: BMS-986465 is under development for the treatment...